Skip to main content
Download PDF

The infantile neuroaxonal dystrophy rating scale (INAD-RS)

Orphanet Journal of Rare Diseases volume 15, Article number: 195 (2020) Cite this article

Abstract

Background

INAD is an autosomal recessive neurogenetic disorder caused by biallelic pathogenic variants in PLA2G6. The downstream enzyme, iPLA2, plays a critical role in cell membrane homeostasis by helping to regulate levels of phospholipids. The clinical presentation occurs between 6 months and 3 years with global developmental regression, hypotonia, and progressive spastic tetraparesis. Progression is often rapid, resulting in severe spasticity, visual impairment, and cognitive decline, with many children not surviving past the first decade of life. To date, no accepted tool for assessing the severity of INAD exists; other commonly used scales (e.g. CHOP-INTEND, Modified Ashworth, Hammersmith Functional Motor Scale) do not accurately gauge the current severity of INAD, nor are they sensitive/specific enough to monitor disease progression. Finally, these other scales are not appropriate, because they do not address the combination of CNS, peripheral nerve, and visual pathology that occurs in children with INAD.

Methods

We have developed and validated a structured neurological examination for INAD (scored out of 80). The examination includes six main categories of pediatric developmental evaluation: 1) gross motor-and-truncal-stability skills, 2) fine motor skills, 3) bulbar function, 4) ocular function, 5) temporo-frontal function, and, 6) Functional evaluation of the autonomic nervous system. A cohort of patients diagnosed with INAD were followed prospectively to validate the score against disease severity and disease progression.

Results

We show significant correlation between the total neurological assessment score and months since symptom onset with a statistically significant (p = 6.7 × 10− 07) correlation between assessment score and disease onset. As hypothesized, the coefficient of months-since-symptom-onset is strongly negative, indicating a negative correlation between total score and months since symptom onset.

Conclusion

We have developed and validated a novel neurological assessment score in INAD that demonstrates strong correlation with disease severity and disease progression.

Introduction

Infantile neuroaxonal dystrophy (INAD, NBIA2A; MIM# 256600) is a major subtype of PLA2G6-associated neurodegeneration (PLAN), a heterogenous group of clinical disorders with varying severity comprising INAD, atypical neuroaxonal dystrophy (NBIA2B; MIM# 610217) and adult-onset dystonia-parkinsonism (PARK14; MIM# 612953). PLAN is caused by biallelic pathogenic variants in PLA2G6, and the specific phenotype of PLAN is based on various clinical, genotype-phenotype, neurophysiologic, radiographic, and laboratory features [1, 2].

The onset of INAD typically occurs between 6 months and 3 years of age, commonly presenting with psychomotor regression, gait disturbance, truncal hypotonia, and in some patients, strabismus and nystagmus. The disease progresses into spastic tetraparesis with symmetric pyramidal signs, progressive cognitive decline, loss of vocalization, optic atrophy, and bulbar dysfunction. The progression is usually rapid and patients rarely survive beyond their first decade, even with supportive care [3,4,5,6]. Seizures may present early or late in the disease course but are reported in only a minority of patients [4, 6,7,8,9]. Histopathology may show the presence of axonal spheroid bodies in both the central and peripheral nervous system [6, 7, 10], and neuroimaging usually reveals pathognomonic inferior cerebellar atrophy; in some cases, iron accumulation is seen in the globus pallidus. Given its ultra-orphan status, no consensus guidelines exist on the management and treatment of INAD. With no approved therapies, the management of INAD remains supportive, with symptomatic treatment for issues such as contractures (e.g. physical therapy) and feeding difficulties (e.g. feeding support) the mainstay of treatment.

The status of INAD as an ultra-orphan disease has limited the ability to report on clinical observations in significant numbers of patients in any one study, and there is currently a lack of any meaningful measures of disease status or progression. To date, no accepted tool for assessing the severity of INAD exists; other commonly used scales (e.g. CHOP-INTEND, Modified Ashworth, Hammersmith Functional Motor Scale) do not accurately gauge the current severity of INAD, nor are they sensitive/specific enough to monitor disease progression. Finally, these other scales are not appropriate, because they do not address the combination of CNS, peripheral nerve, and visual pathology that occurs in children with INAD.

Although the clinical progression of INAD has been documented in prior natural history studies, these studies were retrospective and may or may not have captured the full spectrum of manifestations of INAD due to their retrospective nature or the patterns of decline [11]. This present prospective collection of 40 genetically confirmed cases represents the largest cohort of INAD patients reported to date, and thus is the most comprehensive cohort available to create a meaningful clinical outcome assessment (COA). A meaningful COA of INAD could serve as an accurate measure of natural history and progression, and further refine it from existing cohorts [12]. In addition, until disease-modifying therapies become available, these data have valuable confirmatory diagnostic and prognostic value for clinicians, patients, and families.

This report describes a clinical rating scale for INAD, INAD-RS, which takes into account the six main categories of pediatric developmental evaluation: 1) gross motor-and-truncal-stability skills, 2) fine motor skills, 3) bulbar function, 4) ocular function, 5) temporo-frontal function, and, 6) Functional evaluation of the autonomic nervous system. It is designed such that each category of efficacy measures how patients function in daily tasks and interactions. While most are function-oriented with clear outcomes on patient performance (e.g. gross motor, fine-motor), some, such as bulbar function, are critical to ADLs and vital functions such as feeding and survival. In aggregate, the items on INAD-RS directly assess a patient’s 1) ability to carry on daily life activities (function) including those critical for survival, 2) ability to interact with their environment and caregivers, and 3) symptomatic status related to how they feel.

Materials and methods

Ethical approval

An IRB-approved written informed consent was obtained from all patients and their parents enrolled in this study.

Scale development

The first step we took was to collate and cross-examine expertise of key opinion leader (KOL) pediatric neurologists, which included some authors of this paper, the author’s medical expertise in neurogenetics (including US board-certifications in clinical genetics, medical biochemical genetics, pediatric neurology), and our own medical examinations of 40 INAD patients with a range of severity. Subsequently we created a standardized a scoring system of 40 specific assessment measures of either ADLs or vital functions that are abnormal in INAD, named INAD-RS. We also imported elements of age-appropriate (adjusted for disease state), clinically meaningful, validated, and standardized scales used in other pediatric neuro-degenerative diseases such as the Bayley Motor Scale. Details on adaptions describing the development of assessment measures are outlined in supplementary document 2 entitled ‘INAD Rating Scale Development Scoring Table’.

Goals and limitations of INAD-RS

INAD-RS is not designed to diagnose INAD; rather, its purpose is to quantify disease status and disability, however, it may be of value in the early evaluation of an infant with regressive features to confirm the suspicion of INAD before MRI or molecular diagnostic confirmation. Given this purpose, it aims to include all areas of clinical impairment observed in INAD as outlined above. INAD-RS is designed primarily for pediatric neurologists as a routine part of clinical care and monitoring. The scale takes ~ 10 min to complete and requires minimal supportive apparatus (e.g. a small block and a toy to attract child’s attention). One part of the examination, assessment of optic pallor, may require an ophthalmologist’s input if indirect fundoscopy is not possible. The other parts of the ocular exam require familiarity with assessments of nystagmus and strabismus and the range of possible severity of these signs that can only be acquired through clinical acumen and experience.

INAD-RS is intended to serve as a global, convenient measure of INAD disease status and progression and could be used in early stages of interventional studies or as a meaningful measure of progression in individuals or groups.

Subjects and scale administration

All patients examined had a molecularly confirmed diagnosis of INAD via identification of bi-allelic pathogenic variants in PLA2G6. Patients were evaluated across multiple centers, including two sites in North America, and individual sites in China, Egypt, India, and Tunisia. All examinations were videotaped and reviewed for inter-rater reliability (see section on Inter-rater reliability). All examiners received prior training on the scale by way of discussion with an experienced examiner, and/or a training manual (Supplementary Document 1), and/or observing prior videos of high, medium, low scoring patients.

The month and year of symptom onset was determined by detailed history taking. In most cases, the first symptoms were gross motor, such as delays in balance or walking and/or developmental regression. The date of symptom onset was recorded as month and year. The date of each visit was entered as month/day/year. In addition, year of birth and age at time of assessment were obtained from medical records and family reports.

Scale content

We designed INAD-RS so that each category measures how the patients function in daily tasks and interactions. While most are function-oriented with clear outcomes on patient performance (e.g. gross motor, fine-motor), including socialization and communication skills some, such as bulbar function, are critical to ADLs and vital functions such as feeding and survival. INAD-RS is a combination of history and physical exam questions. In aggregate, the preponderance of the elements directly assess a patient’s 1) ability to carry on daily life activities (function) including those critical for survival, 2) ability to interact with their environment and caregivers, and 3) symptomatic status related to how they feel.

The INAD-RS is comprised of 40 items in six sub-categories of assessment, 1) Gross Motor Skills (24 points total), 2) Fine Motor Skills (12 points total), 3) Bulbar Function (14 points total), 4) Ocular (10 points total), 5) Temporo-frontal (16 points total), and, 6) Autonomic (4 points total). Each skill assessment is scored 0, 1, 2; higher score correlates with better performance. Table 1 shows the items of the definitions of each level of score and comments for each item. A normal child would have score of 80, 2 on each function × 40 and as the disease progresses the score declines. Of note, particularly young children may not have reached all normal developmental milestones at time of assessment (e.g. standing unaided) and these factors should be considered.

Table 1 The infantile neuroaxonal rating scale with comments and instructions
Full size table

Results

In total, there were 40 subjects with molecularly confirmed INAD examined at a range of 10–94 months since symptom onset (mean 39.4 months, SD 22.76). The INAD-RS score range was 7–69 (mean 34.78, SD 16.01). Patients who fit the phenotype of atypical INAD (ANAD) were excluded from the analysis. We found a strong correlation between the scale score and months since symptom onset (r2 = 0.48). This was a statistically significant correlation (p = 6.7 × 10− 7). We found the months since symptom onset to be the most sensitive indicator of disease progression, more sensitive than absolute age because of the frequent delay in diagnosis. In our experience, the rare nature of INAD make it a challenging diagnosis, and families are often on a diagnostic odyssey despite parental and medical awareness the child is not developing normally. This delay between symptom onset and diagnosis is in line with other pediatric genetic diseases [2, 11, 13,14,15,16,17,18,19].

Intra-rater reliability

In a subset of 19 patients, the same examiner performed INAD-RS 2–4 weeks apart to demonstrate validity and reproducibility of INAD-RS. We found no statistically significant difference between the two visits, which demonstrates strong intra-rater reliability of INAD-RS. Means were 35.79 and 36.1 respectively for the two visits with a p-value for a statistically significant difference calculated to be 0.95, thus the null hypothesis of a mean difference of zero stands (t-test: two-sample assuming unequal variances).

Inter-rater reliability

The INAD-RS neurological examinations were performed by the same examiner, under identical circumstances for each examination when possible, and under well-lit conditions with video recording and description. In general, these videos were of high quality with clear documentation of which part of INAD-RS was being performed, and the score awarded per assessment. Some examples of video narration included text overlays on video, and verbal calling out of score after each assessment on the scale. The authors independently reviewed the videos and assigned scores to each patient, blinded to the score of the original examiner, and we found no statistically significant difference between our scores and the examiner scores in all six domains demonstrating strong inter-rater reliability (t-test: two-sample assuming unequal variances).

In addition, we have experience in training other pediatric neurologists in performing INAD-RS. To date we have trained ten clinicians on how to perform INAD-RS by way of video conferencing with an experienced examiner. All of these training sessions lasted less than 1 h, and averaged ~ 30 min, with all trained clinicians verbalizing confidence in their ability to perform INAD-RS. Subsequent real-time observation of a subset of these trained clinicians validated their competence in performing INAD-RS.

Rate of progression

Rate of progression (see Fig. 1) on INAD-RS was calculated using a linear regression model applied to the cross-sectional data on the 40 subjects. The mean rate of progression was 0.49 points per month of symptoms (Standard error 00.08, lower 95% -0.658, upper 95% -0.324). There was no statistically significant difference between males and females. Interestingly, the best fit trend line is logarithmic (r2 = 0.54), and the linear trend line r2 is 0.48. The reason for a logarithmic slope more closely correlating with progression appears to be the increased loss of function earlier in the disease compared with later in the disease. Indeed, once many milestones have been lost, the residual function has less variance to ascertain differences. 60% of the maximum potential loss in the INAD-RS occurs within 40 months of onset of symptoms and this provides and optimum window for potential therapeutic intervention.

Fig. 1
figure 1

INAD-RS Progression. Figure showing months since symptom onset on X-axis and neurological score on Y-Axis. There is a negative correlation and an average loss of 0.49 points per month of symptoms. The best fit trend line is logarithmic (r2 = 0.54)

Full size image

Discussion

INAD-RS represents the first clinical outcome assessment derived specifically for INAD. The scale was created using the largest prospective cohort of INAD patients collected to date. The second largest cohort of 28 subjects, by Altuame et al. [11], consisted of a retrospective chart review and that study provided the most comprehensive overview of the natural history of INAD to our knowledge. We add to this literature by providing detailed disease progression data on a neurological scale tailored to INAD and documenting a pre-defined prospective exam on 40 patients.

One additional benefit of our scale is the ability to discern if a child is following the clinical course of INAD or atypical NAD (aNAD). While in general INAD presents sooner, some overlap exists and initially it can be challenging to differentiate between them. In some cases, the difference is only apparent as the disease progresses. In our experience monitoring a child longitudinally with INAD-RS using their months since symptom onset, it is quickly apparent if they are following a course of INAD or aNAD. To date, INAD-RS has not been used to assess aNAD or other PLAN disorders. We posit there may be a role for future studies to assess the utility of INAD-RS as a meaningful clinical outcome assessment in these and other conditions with a similar clinical phenotype.

Concerning limitations of INAD-RS, in general our experience with INAD-RS has shown us that it can be a convenient measure of clinical status and disability in INAD and be used as a meaningful tool to monitor progression. While we have demonstrated robust intra-rater and inter-rater reliability, some bias and difference in clinical experience will mean that scores will never correlate perfectly; however, this can be said of the majority of clinical assessment scales. INAD-RS also requires the examiner to be skilled and experienced in clinical examination of pediatric neurology and some of the markers require prior knowledge of normal clinical signs in this population.

Another limitation is these data represent a cross-sectional aggregate, and as such additional longitudinal data on each patient will be useful to monitor individual patient progression, and to look for other variables influencing progression, such as underlying genotype. The presence of a single truncating variant has previously been shown to be associated with more severe progression with a statistically significant difference [11]. Specifically Altuame et al. noted a statistical significant difference with the presence of a truncating variant in the time of initial concern (p = 0.04), initial loss of language (p = 0.001), initial loss of fine motor skills (p = 0.009), and initial loss of bulbar skills (p = 0.007). These significant differences were not observed in this cohort based on baseline cross-sectional analysis; however longitudinal monitoring which includes rate of progression to assess whether underlying genotype is affecting the phenotype should be performed at a future date to confirm this prior observation. Mechanistically regarding genotype-phenotype correlations in biochemical genetics, more severe mutations tend to result in less functional enzyme and thus infer a more severe phenotype; this is observed in other genetic disorders of enzymatic function and metabolism [2, 20,21,22,23,24].

Conclusions

In conclusion, we report on a novel clinical outcome assessment tool for INAD. INAD-RS demonstrates a strong correlation between the scale score and months since symptom onset (logarithmic r2 = 0.54). There is a statistically significant correlation between the INAD-RS score and months since symptom onset (p = 6.7 × 10− 7). This scale assesses all six major domains of neurological sequelae in INAD, and thus assess a much more holistic view of INAD than the other scales (e.g. CHOP-INTEND, Hammersmith, Modified Ashworth). We are confident that we have developed and validated a novel neurological assessment score in INAD that demonstrates strong correlation with disease severity and disease progression. Given this strong correlation, we posit that INAD-RS would be suitable for a primary endpoint measure of disease monitoring and/or progression.

Availability of data and materials

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

Abbreviations

aNAD:

Atypical infantile neuroaxonal dystrophy

COA:

Clinical outcome assessment

INAD:

Infantile neuroaxonal dystrophy

INAD-RS:

Infantile neuroaxonal dystrophy rating scale

PLAN:

PLA2G6-associated neurodegeneration

References

  1. Wang ZB, Liu JY, Xu XJ, Mao XY, Zhang W, Zhou HH, et al. Neurodegeneration with brain iron accumulation: insights into the mitochondria dysregulation. Biomed Pharmacother. 2019;118:109068.

    Article  CAS  Google Scholar 

  2. Adams D, Midei M, Dastgir J, Flora C, Molinari RJ, Heerinckx F, et al. Treatment of infantile neuroaxonal dystrophy with RT001: a di-deuterated ethyl ester of linoleic acid: report of two cases. JIMD Rep. 2020;54(1):54–60.

  3. Khateeb S, Flusser H, Ofir R, Shelef I, Narkis G, Vardi G, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet. 2006;79(5):942–8.

    Article  CAS  Google Scholar 

  4. Kurian M, Morgan N, MacPherson L, Foster K, Peake D, Gupta R, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology. 2008;70(18):1623–9.

    Article  CAS  Google Scholar 

  5. Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. PLA2G6-associated neurodegeneration. GeneReviews®. Seattle: University of Washington; 2017.

    Google Scholar 

  6. Gregory A, Westaway S, Holm IE, Kotzbauer P, Hogarth P, Sonek S, et al. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology. 2008;71(18):1402–9.

    Article  CAS  Google Scholar 

  7. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009;46(2):73–80.

    Article  CAS  Google Scholar 

  8. Carrilho I, Santos M, Guimarães A, Teixeira J, Chorão R, Martins M, et al. Infantile neuroaxonal dystrophy: what’s most important for the diagnosis? Eur J Paediatr Neurol. 2008;12(6):491–500.

    Article  Google Scholar 

  9. Wu Y, Jiang Y, Gao Z, Wang J, Yuan Y, Xiong H, et al. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. Eur J Neurol. 2009;16(2):240–5.

    Article  CAS  Google Scholar 

  10. Tonelli A, Romaniello R, Grasso R, Cavallini A, Righini A, Bresolin N, et al. Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy. Clin Genet. 2010;78(5):432–40.

    Article  CAS  Google Scholar 

  11. Altuame FD, Foskett G, Atwal PS, Endemann S, Midei M, Milner P, et al. The natural history of infantile neuroaxonal dystrophy. Orphanet J Rare Dis. 2020;15(1):109.

    Article  Google Scholar 

  12. Powers JH 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2–14.

    Article  Google Scholar 

  13. Blackburn PR, Xu Z, Tumelty KE, Zhao RW, Monis WJ, Harris KG, et al. Bi-allelic alterations in AEBP1 Lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlers-Danlos syndrome. Am J Hum Genet. 2018;102(4):696–705.

    Article  CAS  Google Scholar 

  14. Atwal PS, Blease S, Braxton A, Graves J, He W, Person R, et al. Novel X-linked syndrome of cardiac valvulopathy, keloid scarring, and reduced joint mobility due to filamin A substitution G1576R. Am J Med Genet A. 2016;170(4):891–5.

    Article  CAS  Google Scholar 

  15. Macklin SK, Jackson JL, Atwal PS, Hines SL. Physician interpretation of variants of uncertain significance. Familial Cancer. 2019;18(1):121–6.

    Article  Google Scholar 

  16. Reichold M, Klootwijk ED, Reinders J, Otto EA, Milani M, Broeker C, et al. Glycine Amidinotransferase (GATM), renal Fanconi syndrome, and kidney failure. J Am Soc Nephrol. 2018;29(7):1849–58.

    Article  CAS  Google Scholar 

  17. Mohammad AN, Bruno KA, Hines S, Atwal PS. Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement. Mol Genet Metab Rep. 2018;15:11–4.

    Article  Google Scholar 

  18. Donti TR, Cappuccio G, Hubert L, Neira J, Atwal PS, Miller MJ, et al. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Mol Genet Metab Rep. 2016;8:61–6.

    Article  CAS  Google Scholar 

  19. Darcy D, Atwal PS, Angell C, Gadi I, Wallerstein R. Mosaic paternal genome-wide uniparental isodisomy with Down syndrome. Am J Med Genet A. 2015;167(10):2463–9.

    Article  Google Scholar 

  20. Sunde K, Blackburn PR, Cheema A, Gass J, Jackson J, Macklin S, et al. Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS). Mol Genet Metab Rep. 2016;9:94–7.

    Article  Google Scholar 

  21. Donti TR, Blackburn PR, Atwal PS. Holocarboxylase synthetase deficiency pre and post newborn screening. Mol Genet Metab Rep. 2016;7:40–4.

    Article  CAS  Google Scholar 

  22. Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, et al. Silent Tyrosinemia type I without elevated tyrosine or Succinylacetone associated with liver cirrhosis and hepatocellular carcinoma. Hum Mutat. 2016;37(10):1097–105.

    Article  CAS  Google Scholar 

  23. Atwal PS, Brennan M-L, Cox R, Niaki M, Platt J, Homeyer M, et al. Clinical whole-exome sequencing: are we there yet? Genet Med. 2014;16(9):717–9.

    Article  Google Scholar 

  24. Atwal P. Mutations in the complex III assembly factor tetratricopeptide 19 gene TTC19 are a rare cause of Leigh syndrome. JIMD Rep. 2013;14:43–5 Springer, Berlin, Heidelberg.

    Article  Google Scholar 

Download references

Acknowledgments

We would like to thank the patients and families in their help to create INAD-RS.

Funding

No funding sources are declared. The authors would like to thank the patients and families for their permission to publish this manuscript.

Author information

Authors and Affiliations

  1. Retrotope Inc., Los Altos, CA, USA

    Paldeep S. Atwal, Mark Midei, Frederic Heerinckx & Peter Milner

  2. Atlantic Medical Group, Morris Township, NJ, USA

    Darius Adams

  3. University of California San Francisco (UCSF), San Francisco, CA, USA

    Alexander Fay

Authors
  1. Paldeep S. Atwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Midei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darius Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Fay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederic Heerinckx
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Milner
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors above made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work AND drafting the work or revising it critically for important intellectual content AND gave final approval of the version to be published AND agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Paldeep S. Atwal.

Ethics declarations

Ethics approval and consent to participate

An IRB-approved written informed consent was obtained from all patients and their parents enrolled in this study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declarations of 1975, as revised in 2000 [5].

Consent for publication

An IRB-approved written informed consent was obtained from all patients and their parents enrolled in this study with respect to publication. All subjects reported in this manuscript have provided consent for publication, although the reports are anonymous and does not contain personal information. Proof of informed consent is available upon request.

Competing interests

Paldeep S. Atwal, Mark Midei, Frederic Heerinckx, Peter Milner, are employed by, and hold stock in Retrotope, Inc. All other authors have no potential conflicts of interest. All authors confirm that the content of the article has not been influenced by the sponsor.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Supplementary Document 1.

INAD Neurological Assessment Instruction Manual.

Additional file 2: Supplementary Document 2.

INAD Rating Scale Development Scoring Table.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atwal, P.S., Midei, M., Adams, D. et al. The infantile neuroaxonal dystrophy rating scale (INAD-RS). Orphanet J Rare Dis 15, 195 (2020). https://doi.org/10.1186/s13023-020-01479-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-020-01479-5

Keywords

Orphanet Journal of Rare Diseases

ISSN: 1750-1172